Absci Corporation reported fourth quarter and full year 2025 financial results with Q4 revenue of $0.7 million and net loss of $29.6 million, and full year revenue of $2.8 million and net loss of $115.2 million. The company dosed first three cohorts in the ABS-201 Phase 1/2a HEADLINE trial, unveiled supporting ex vivo data, appointed Ransi Somaratne as Chief Medical Officer, and stated cash sufficient into first half of 2028.
Key takeaways
Successfully dosed first three cohorts in single ascending dose portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety data.
Appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer.
Cash, cash equivalents, and marketable securities of $144.3 million as of December 31, 2025, sufficient to fund operations into first half of 2028.
Q4 2025 revenue $0.7 million vs $0.7 million same quarter 2024; net loss $29.6 million or $(0.20) per share vs $29.0 million or $(0.25) per share.
Full year 2025 revenue $2.8 million vs $4.5 million 2024; net loss $115.2 million or $(0.84) per share vs $103.1 million or $(0.94) per share.